Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 4/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1564206 | 0.84 | KDM4E (0.39) | KMT2AALDH1A1HSD17B10 | |
| SCHEMBL14191967 | 0.83 | IKBKB (0.39) | IKBKBJAK2JAK3MEN1KMT2A | |
| SCHEMBL10135175 | 0.81 | MEN1 (0.47) | IKBKBJAK2JAK3MEN1KMT2A | |
| SCHEMBL7055093 | 0.78 | IKBKB (0.43) | IKBKBJAK2JAK3MEN1KMT2A | |
| SCHEMBL491042 | 0.77 | IKBKB (0.55) | IKBKBJAK2JAK3MEN1KMT2A | |
| SCHEMBL5207334 | 0.76 | IKBKB (0.54) | IKBKBJAK2JAK3MEN1KMT2A | |
| SCHEMBL5096597 | 0.74 | PTK2 (0.56) | KMT2AALDH1A1HSD17B10 | |
| SCHEMBL5105544 | 0.74 | MEN1 (0.59) | IKBKBJAK2JAK3MEN1KMT2A | |
| Bicarbonate SCHEMBL5978745 | 0.72 | IKBKB (0.50) | IKBKBJAK2JAK3MEN1KMT2A | |
| Bicarbonate SCHEMBL5978736 | 0.72 | IKBKB (0.50) | IKBKBJAK2JAK3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106091-B2 | Inhibitors of IKK-beta serine-threonine protein kinase | CHROMA THERAPEUTICS LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| US-8106091-B2 | Inhibitors of IKK-beta serine-threonine protein kinase | CHROMA THERAPEUTICS LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| EP-2078007-B1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-08-31 | — | — | EP | disclosed |
| US-8003695-B2 | IKK-beta serine-threonine protein kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003695-B2 | IKK-beta serine-threonine protein kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20110046210-A1 | SUBSTITUTED THIOPENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| US-20110039920-A1 | INHIBITORS OF IKK-BETA SERINE-THERONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2011-02-17 | — | — | US | disclosed |
| WO-2010122294-A1 | THIOPHENE INHIBITORS OF IKK-B SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | Chroma Terapeutics Ltd (GB) | 2010-04-08 | — | — | US | disclosed |
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | Chroma Terapeutics Ltd (GB) | 2010-04-08 | — | — | US | disclosed |
| US-20100069473-A1 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2010-03-18 | — | — | US | disclosed |
| US-20100069473-A1 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2010-03-18 | — | — | US | disclosed |
| WO-2009130434-A1 | INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2009-10-29 | — | — | WO | disclosed |
| US-7375131-B2 | NF-κB inhibitors | SMITHKLINEBEECHAM CORP. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375131-B2 | NF-κB inhibitors | SMITHKLINEBEECHAM CORP. (US) | 2008-05-20 | — | — | US | disclosed |
| WO-2008053182-A1 | IKK-β SERINE-THREONINE PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2008-05-08 | — | — | WO | disclosed |
| EP-1532133-A4 | NF-:B INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20050165087-A1 | For treating diseases with aminothiophene inhibitors of IKK-beta phosphorylation of I kappa B, including inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease | CALLAHAN JAMES F (US) | 2005-07-28 | — | — | US | disclosed |
| EP-1532133-A1 | NF-:B INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2003104218-A1 | NF-:B INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046210-A1 | SUBSTITUTED THIOPENECARBOXAMIDES AS IKK-BETA SERINE-, THREONINE-PROTEIN KINASE INHIBITORS | IKBKE, CSNK1A1, CSNK1E | IKBKB 7/4885JAK2 593/4885JAK3 542/4885 |
| US-20100069473-A1 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase | IKBKB, IKBKE, CHUK | IKBKB 1/4885JAK2 1292/4885JAK3 401/4885 |
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | IRAK3, IKBKE, IRAK1 | IKBKB 5/4885JAK2 984/4885JAK3 338/4885 |
| US-20050165087-A1 | For treating diseases with aminothiophene inhibitors of IKK-beta phosphorylation of I kappa B, including inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease | NFKBIA, IKBKG, IKBKE | IKBKB 4/4885JAK2 260/4885JAK3 157/4885 |
| US-20110039920-A1 | INHIBITORS OF IKK-BETA SERINE-THERONINE PROTEIN KINASE | CSNK1E, PACSIN2, CHUK | IKBKB 5/4885JAK2 1460/4885JAK3 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.